(b) Ligand-independent model: Clinical observations have found mutations of PTCH-1 and PTCH-2 in basal cell carcinomas and in medulloblastomas, resulting in dysregulated GLI signaling due to ineffective sequestration of SMO signaling, regardless of SHh ligand levels. This evidence concerns the gene PTCH1 and basal cell carcinoma.